Adventrx Pharmaceuticals (ANX -3%) says it's commenced dosing in its QT/QTc study of ANX-188. The study will assess whether or not the drug has an effect on QT prolongation, which can potentially lead to malignant cardiac rhythm disturbances, as part of an FDA requirement to assess cardiac repolarization for most new drugs having systemic bioavailability. The dosing is expected to be completed in the first quarter, and results ae anticipated in the second quarter of 2013.
Adventrx Pharmaceuticals (ANX -3%) says it's commenced dosing in its QT/QTc study of ANX-188....
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs